By Michael Dabaie

 

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. said Thursday that the U.S. Food and Drug Administration approved Darzalex in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

The approval is based on results from a Phase 3 clinical study, which showed the combination regimen reduced the risk of disease progression or death by 44% in newly diagnosed patients who are transplant ineligible, Janssen said.

This is the sixth Darzalex FDA-approved use in multiple myeloma and the second for newly diagnosed patients, the company said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

June 27, 2019 15:03 ET (19:03 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Johnson and Johnson Charts.